These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2386940)

  • 41. Pharmacology and toxicology of a seven-day infusion of 1-beta-D-arabinofuranosylcytosine plus uridine in dogs.
    Perlow L; Ohnuma T; Andrejczuk A; Shafir M; Strauchen J; Holland JF
    Cancer Res; 1985 Jun; 45(6):2572-7. PubMed ID: 3986795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
    Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytotoxicity of paclitaxel in combination with cisplatin and a new Pt-mercaptopyridine complex.
    Ragazzi E; D'Ancona S; Berti E; Carrara M
    Anticancer Res; 2002; 22(5):2783-8. PubMed ID: 12529997
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of synergism of drugs cis-diamminedichloroplatinum (II) and arabinosylcytosine on the level of chemical interaction with DNA and on the growth of mouse leukemia.
    Rauko P; Novotný L; Reichelová V; Balázová E
    Gen Pharmacol; 1991; 22(5):805-10. PubMed ID: 1761184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interaction index and different methods for determining drug interaction in combination therapy.
    Lee JJ; Kong M; Ayers GD; Lotan R
    J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of cis-diamminedichloroplatinum on DNA incorporation and cytotoxicity of 1-beta-D-arabinofuranosylcytosine.
    Spriggs DR; Robbins G; Kufe DW
    Biochem Pharmacol; 1986 Dec; 35(23):4297-302. PubMed ID: 3790154
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In silico synergism and antagonism of an anti-tumour system intervened by coupling immunotherapy and chemotherapy: a mathematical modelling approach.
    Hu WY; Zhong WR; Wang FH; Li L; Shao YZ
    Bull Math Biol; 2012 Feb; 74(2):434-52. PubMed ID: 21972030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alternatives to Rothman's approach for assessing synergism (or antagonism) in cohort studies.
    Hogan MD; Kupper LL; Most BM; Haseman JK
    Am J Epidemiol; 1978 Jul; 108(1):60-7. PubMed ID: 685976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interaction of cytotoxic agents: a rule-based system for computer-assisted cell survival analysis.
    Gentile FP; Chiatti L; Mauro F; Briganti G; Floridi A; Benassi M
    Anticancer Res; 1992; 12(3):637-43. PubMed ID: 1622119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monotone smoothing with application to dose-response curves and the assessment of synergism.
    Kelly C; Rice J
    Biometrics; 1990 Dec; 46(4):1071-85. PubMed ID: 2085626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Zero interaction response surfaces, interaction functions and difference response surfaces for combinations of biologically active agents.
    Sühnel J
    Arzneimittelforschung; 1992 Oct; 42(10):1251-8. PubMed ID: 1472147
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A flexible unified approach to the analysis of pre-clinical combination studies.
    Harbron C
    Stat Med; 2010 Jul; 29(16):1746-56. PubMed ID: 20572122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of methods for evaluating drug-drug interaction.
    Zhao L; Au JL; Wientjes MG
    Front Biosci (Elite Ed); 2010 Jan; 2(1):241-9. PubMed ID: 20036874
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example.
    White DB; Slocum HK; Brun Y; Wrzosek C; Greco WR
    Curr Drug Metab; 2003 Oct; 4(5):399-409. PubMed ID: 14529372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
    Chou TC
    Pharmacol Rev; 2006 Sep; 58(3):621-81. PubMed ID: 16968952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram.
    Tallarida RJ; Raffa RB
    Life Sci; 1996; 58(2):PL 23-8. PubMed ID: 8606615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Communicating synergism in drug combination studies.
    Brodkin J; Shannon HE
    Arzneimittelforschung; 2000 Aug; 50(8):765-7. PubMed ID: 10994162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Application and review of the separate ray model to investigate interaction effects.
    Straetemans R; Bijnens L
    Front Biosci (Elite Ed); 2010 Jan; 2(1):266-78. PubMed ID: 20036877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mixture effects of chemicals: The difficulty to choose appropriate mathematical models for appropriate conclusions.
    Lasch A; Lichtenstein D; Marx-Stoelting P; Braeuning A; Alarcan J
    Environ Pollut; 2020 May; 260():113953. PubMed ID: 31962267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships.
    Zhao L; Au JL; Wientjes MG
    Curr Cancer Drug Targets; 2017; 17(8):735-755. PubMed ID: 28359247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.